ArticleFrontiers in cell and developmental biology2026
An exploratory analysis of disulfidptosis-related gene signatures in minimal change disease identifies metabolic and immune associations.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: We aimed to investigate the association between genes related to disulfidptosis-a form of cell death caused by aberrant disulfide stress and cytoskeletal collapse-and the molecular features of minimal change disease (MCD), the leading cause of primary nephrotic syndrome. Methods: Data from the GeneCards and Gene Expression Omnibus (GEO) databases were integrated to systematically analyze disulfidptosis-related genes in MCD. Machine learning approaches-including generalized linear model (GLM), support vector machine (SVM), random forest (RF), and extreme gradient boosting (XGBoost)-pinpointed four hub genes. These genes were used to construct a diagnostic nomogram. Molecular groups were defined by consensus clustering, and pathway alterations were explored through gene set variation analysis and gene set enrichment analyses. Gene expression was validated by immunohistochemistry (IHC) and immunofluorescence (IF). Results: The diagnostic model based on Conclusion: This study indicates a potential link between disulfidptosis-related genes and MCD, and presents an exploratory diagnostic and molecular classification system that requires further validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.